Phage display identification of MCR-1-targeting nanobodies to restore colistin susceptibility
The spread of antimicrobial resistance among gram-negative bacilli, particularly within Enterobacteriaceae and non-fermentative gram-negative bacilli, poses a serious and escalating threat to global public health. Colistin, a cationic antimicrobial peptide, remains a last-line treatment for infections caused by multidrug-resistant gram-negative bacteria. However, the global dissemination of the plasmid-encoded colistin resistance gene mobilized colistin resistance-1 ( mcr-1 ) has contributed to increasing cases of colistin resistance and threatens global health. Nanobodies offer advantages, including high affinity, stability, and small size. Here, we isolated anti-MCR-1.1 nanobodies from a phage-display library and evaluated their potential to restore colistin efficacy. The periplasmic catalytic domain of MCR-1.1 was purified by affinity chromatography and used to immunize alpacas, resulting in the construction of a phage-displayed nanobody library against MCR-1.1 with a size of 5.8 × 10⁸ CFU. After biopanning, several anti-MCR-1.1 nanobodies specific for the periplasmic catalytic domain of MCR-1.1 were successfully isolated. Among them, high-affinity nanobodies Nb7, Nb12, Nb24, and Nb30 were selected in vitro , with Nb30 demonstrating promising activity. Following engineering, the Nb30-1 variant was generated and shown to exhibit enhanced efficacy. In combination with colistin, Nb30-1 effectively inhibited the growth of colistin-resistant, MCR-1.1-expressing laboratory Escherichia coli BL21(DE3), as determined by the growth dynamics curve. Molecular docking analysis revealed the binding interactions between Nb30/Nb30-1 and the MCR-1.1 protein, and affinity measurements confirmed their high binding affinity for the MCR-1.1 antigen. Given the exquisite conservation of key catalytic residues and the epitope recognized by Nb30-1 across MCR-1 variants, Nb30-1 represents a promising macromolecular adjuvant strategy to overcome MCR-1-mediated resistance. IMPORTANCE The escalating use of antibiotics has driven a global rise in antibiotic resistance, underscoring an urgent need for adjuvants that can restore the susceptibility of drug-resistant bacteria. In this study, we isolate anti-MCR-1 nanobodies from a phage-display library and evaluate their potential to restore colistin efficacy. Following engineering, the Nb30-1 variant was generated and shown to exhibit enhanced efficacy. These findings suggest that engineered anti-MCR-1 nanobodies, particularly Nb30-1, represent a promising therapeutic strategy to combat MCR-1-positive colistin-resistant bacterial infections by resensitizing bacteria to colistin.
Authors
- Chenyu Lou
- Lanjie Ren
- Manping Gu
- Li Zhang (ORCID: https://orcid.org/0000-0003-3115-8196)
- Qiming Li (ORCID: https://orcid.org/0000-0002-6916-3954)
- Yajie Zhao
- Suxia Wu (ORCID: https://orcid.org/0009-0007-4911-6660)
- Liang Zhao
- Xu Zhang
Institutions
- Henan University (CN)
- First Affiliated Hospital of Henan University (CN)
Publication Details
- Journal
- Microbiology Spectrum
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1128/spectrum.01904-26
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Health Commission of Henan Province
- Natural Science Foundation of Henan Province